Cellular therapies beyond CAR-T—including NK cell therapy, TCR-engineered T-cells, and tumor-infiltrating lymphocyte (TIL) therapy—are revolutionizing cancer treatment. NK cells attack tumors broadly, TCR-T cells target specific antigens, and TILs harness a patient’s own immune cells to combat cancer. At the Cancer Research and Development Conference 2025, this scientific session will delve into how these therapies are overcoming CAR-T resistance, tackling solid tumors, and advancing personalized oncology. Join us to explore how these breakthroughs reshape immune-driven cancer care and expand global access.